The pathophysiology of major depressive disorder (MDD) is thought to result from impaired
connectivity between key brain networks. Gamma-aminobutyric acid (GABA) is the key …

Evidence suggesting that central nervous system γ-aminobutyric acid (GABA)
concentrations are reduced in patients with major depressive disorder (MDD) has been …

This article reviews novel neurosteroid therapeutics for post-partum depression, with a focus
on their development, clinical trial data, current practices, and future directions in this …

This article describes the critical role of neurosteroids in postpartum depression (PPD) and
outlines the landmark pharmacological journey of brexanolone as a first-in-class …

Postpartum depression (PPD) is one of the three major categories on the spectrum of
postpartum psychiatric syndromes. Postpartum psychiatric syndromes are classified as …

In the past 20 years, our understanding of the pathophysiology of depression has evolved
from a focus on an imbalance of monoaminergic neurotransmitters to a multifactorial picture …

Postpartum depression (PPD) is a common major depressive episode surrounding
childbirth, with estimated rates ranging from 5.5% to 23.5% of all live births across Europe …

Increasing evidence points to an association between major depressive disorders (MDDs)
and diverse types of GABAergic deficits. In this review, we summarize clinical and preclinical …

The GABAergic deficit hypothesis of depression states that a deficit of GABAergic
transmission in defined neural circuits is causal for depression. Conversely, an …

The recent FDA approval of the neurosteroid, brexanolone (allopregnanolone), as a
treatment for women with postpartum depression, and successful trials of a related …